Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Specimen Handling 71Magnetic Resonance Spectroscopy 57Biopsy 44pembrolizumab 40Carboplatin 33Nivolumab 29Radiotherapy 27Cyclophosphamide 27Radiation 26Cisplatin 25Paclitaxel 24olaparib 22Etoposide 19Doxorubicin 18durvalumab 17Taxes 17Radiotherapy, Intensity-Modulated 17Dexamethasone 17Bevacizumab 17X-Rays 16Vincristine 16Prednisone 16Immunoglobulin G 16Disulfides 16Cytarabine 15Platinum 14Pemetrexed 14Leucovorin 14Docetaxel 14atezolizumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × ibritumomab tiuxetan × 30 days × Clear all
NCT00690560 2026-05-22

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Centre Antoine Lacassagne

Phase 2 Completed
30 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡